GlassScriptPhysician profile
Amy D Jones
NPI 1083782023
$5,065.25
in general payments reported to CMS, 2019-2025
22 companies · $458 in 2025
The $458 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $122 · 2022: $735 · 2023: $1,603 · 2024: $2,148 · 2025: $458.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,195 · Education: $13.20.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,194.90 |
| Education | $13.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,071.70 | 2022-2025 | |
| Bausch Health US, LLC | $790.07 | 2021-2025 | Aplenzin, Wellbutrin |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $489.82 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $440.31 | 2022-2025 | Fanapt, Hetlioz |
| Teva Pharmaceuticals USA, INC. | $250.50 | 2022-2025 | Austedo Xr, Austedo Xr, Austedo |
| Tris Pharma INC | $249.74 | 2022-2025 | Dyanavel Xr |
| Axsome Therapeutics, INC. | $220.18 | 2022-2025 | Auvelity, Sunosi |
| Otsuka America Pharmaceutical, INC. | $205.82 | 2021-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $193.68 | 2023-2024 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $173.34 | 2021-2025 | Trintellix |
| Pulmonx Corporation | $149.00 | 2022 | |
| Lundbeck LLC | $146.18 | 2022-2025 | Rexulti |
| Alkermes, INC. | $137.96 | 2021-2024 | Lybalvi |
| Ironshore Pharmaceuticals INC. | $120.46 | 2022-2024 | |
| Astellas Pharma US INC | $73.53 | 2024-2025 | Veozah |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $72.68 | 2023-2024 | Horizant, Horizant |
| Noven Therapeutics, LLC | $69.78 | 2023-2025 | Xelstrym |
| Corium, LLC | $60.86 | 2023-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $57.69 | 2023-2024 | Spravato |
| Emd Serono, INC. | $38.86 | 2025 | |
| Almatica Pharma LLC | $37.79 | 2024-2025 | Loreev Xr |
| Neos Therapeutics, LP | $15.30 | 2023 | Adzenys Xr-Odt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.